Adverum Biotechnologies Inc Cash Flow-to-Debt Ratio
Adverum Biotechnologies Inc cash flow-to-debt ratio. Adverum Biotechnologies Inc (ADVM) has a Cash Flow-to-Debt Ratio of -0.22x as of September 2025, meaning its operating cash flow of $-28.11 Million could theoretically repay 0% of its total liabilities ($128.05 Million) in one year. See Adverum Biotechnologies Inc (ADVM) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Adverum Biotechnologies Inc (2012–2024)
Cash flow-to-debt ratio of Adverum Biotechnologies Inc from 2012 to 2024. Historical debt coverage capacity for Adverum Biotechnologies Inc across 13 annual periods. Check ADVM capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Adverum Biotechnologies Inc Cash Flow-to-Debt Ratio by Year (2012–2024)
Adverum Biotechnologies Inc cash flow-to-debt ratio by year from 2012 to 2024. Year-by-year debt coverage analysis for Adverum Biotechnologies Inc. For the full cash flow conversion analysis, see ADVM cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.85x | $-92.46 Million | $109.13 Million | ▲ +17.5% |
| 2023 | -1.03x | $-90.90 Million | $88.55 Million | ▼ -20.5% |
| 2022 | -0.85x | $-108.09 Million | $126.85 Million | ▲ +2.4% |
| 2021 | -0.87x | $-107.83 Million | $123.54 Million | ▲ +46.9% |
| 2020 | -1.64x | $-79.29 Million | $48.22 Million | ▼ -59.8% |
| 2019 | -1.03x | $-49.17 Million | $47.77 Million | ▲ +76.5% |
| 2018 | -4.38x | $-53.96 Million | $12.33 Million | ▼ -72.3% |
| 2017 | -2.54x | $-45.42 Million | $17.88 Million | ▼ -25.7% |
| 2016 | -2.02x | $-38.37 Million | $18.98 Million | ▲ +32.9% |
| 2015 | -3.01x | $-35.34 Million | $11.73 Million | ▼ -562.8% |
| 2014 | -0.45x | $-5.65 Million | $12.42 Million | ▲ +72.8% |
| 2013 | -1.67x | $-2.17 Million | $1.30 Million | ▼ -82.2% |
| 2012 | -0.92x | $-1.27 Million | $1.38 Million | — |